Retatrutide

Also known as: LY3437943

Weight Loss Phase 3

GLP-1/GIP/Glucagon triple receptor agonist

Mechanism of Action

Activates GLP-1, GIP, and glucagon receptors. The glucagon component may enhance energy expenditure and fat oxidation beyond dual agonists.

5,896
Community Posts
917
Users Discussing
32
Research Articles

Reported Outcomes

Clinical Strength: B (22 trials)

Based on community reports (5,896 posts). Grade reflects frequency and consistency of positive mentions.

A Weight Loss
694 mentions

Reduction in body weight

A Appetite Suppression
550 mentions

Reduced hunger and food cravings

A Sleep Quality
523 mentions

Effects on sleep quality

B Energy Levels
348 mentions

Changes in energy and fatigue levels

B Body Composition
195 mentions

Changes in muscle vs fat ratio

B GI Health
227 mentions

Gastrointestinal effects

C Mental/Mood
153 mentions

Effects on mood and cognitive function

C Cardiovascular
202 mentions

Effects on heart health markers

C Blood Sugar Control
153 mentions

Improved glycemic control and insulin sensitivity

Side Effects

Based on 478 user reports. Frequency indicates how often each was mentioned.

Common (>5%)

Fatigue
Mild 83 reports 12.1%
Constipation
Mild 65 reports 9.5%
Nausea
Mild 56 reports 8.2%

Uncommon (1-5%)

Insomnia
Mild 27 reports 3.9%
Stinging
Mild 26 reports 3.8%
Diarrhea
Mild 19 reports 2.8%
Tiredness
Mild 18 reports 2.6%
Food Noise
Mild 16 reports 2.3%
Water Retention
Mild 15 reports 2.2%
Injection Site Reaction (Isr)
Mild 15 reports 2.2%
Burning
Mild 14 reports 2.0%
Injection Site Pain
Mild 13 reports 1.9%
Hair Loss
Mild 12 reports 1.8%
Increased Resting Heart Rate (Rhr)
Mild 12 reports 1.8%
Increased Heart Rate
Mild 12 reports 1.8%
Sleepiness
Mild 11 reports 1.6%
Anhedonia
Mild 11 reports 1.6%
Exhaustion
Mild 10 reports 1.5%
Increased Hunger
Mild 10 reports 1.5%
Acid Reflux
Mild 10 reports 1.5%

Risks & Warnings

Important safety considerations based on clinical data and community reports.

!

Pancreatitis

7 mentions

Rare but serious. Stop medication and seek care for severe persistent abdominal pain.

!

Thyroid Concerns

27 mentions

GLP-1 agonists carry a boxed warning for thyroid C-cell tumors in rodents. Contraindicated in MEN2 or personal/family history of MTC.

!

Gallbladder Issues

7 mentions

Rapid weight loss increases gallstone risk. Report severe abdominal pain to healthcare provider.

!

Hypoglycemia Risk

27 mentions

Risk increases when combined with insulin or sulfonylureas. Monitor blood sugar carefully.

!

Muscle Loss

22 mentions

Rapid weight loss may include muscle. Adequate protein intake and resistance training recommended.

!

Psychiatric Effects

17 mentions

Monitor for mood changes. Report any concerning psychiatric symptoms to healthcare provider.

!

Hair Loss

8 mentions

May occur with rapid weight loss. Usually temporary (telogen effluvium). Ensure adequate nutrition.

i

Gastrointestinal Issues

224 mentions

GI side effects are the most commonly reported. Usually improve over time with slow titration.

i

Injection Site Reactions

51 mentions

Local reactions are common and usually mild. Rotate injection sites.

Dosing

Standard Protocol

Starting Dose
1-2mg weekly (research protocols)
Titration
Titrate slowly over 4-8 weeks based on tolerance
Half-life
~6 days (estimated)
Administration
Subcutaneous injection, once weekly

Community Dosing Patterns

Based on 889 mentions

Community-reported patterns, not medical advice.

2mg weekly
67
4mg weekly
41
1mg weekly
38
5mg weekly
27
6mg weekly
24

Pricing

Research-grade reference pricing for 10mg vial. Prices vary by vendor and quantity.

We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.

US Research Grade

$100

Single small vial from US domestic vendors

US Research Grade (Bulk)

$52.69

Per-dose equivalent when buying larger US vials

China Research Grade

$5.88

Per-vial when buying 10-pack from Chinese vendors

94% savings

Research

32
Total Articles
22
Clinical Trials
20
Reviews

Key Studies

Enteroendocrine cell regulation of the gut-brain axis Review

Front Neurosci (2023)

Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence Other

Health Sci Rep (2024)

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update Review

Endocrinol Metab (Seoul) (2024)

Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions Review

Gastroenterol Rep (Oxf) (2024)

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Clinical Trial

Nature Medicine (2024)

Commonly Stacked With

Based on 5,896 community posts mentioning Retatrutide.

Cagrilintide 498 mentions (8.4%)
Tirzepatide 410 mentions (7%)
Semaglutide 228 mentions (3.9%)
MOTS-c 113 mentions (1.9%)
BPC-157 60 mentions (1%)

Switching Patterns

Based on 816 discussions about switching to or from Retatrutide.

→ Switching FROM

Tirzepatide 50 mentions
Semaglutide 27 mentions
Cagrilintide 27 mentions
Ipamorelin 4 mentions

Users who switched to Retatrutide

← Switching TO

Cagrilintide 36 mentions
Tirzepatide 24 mentions
Semaglutide 11 mentions
Ipamorelin 6 mentions

Users who switched from Retatrutide

Frequently Asked Questions

What is retatrutide?

Does retatrutide help with weight loss?

How much weight loss can be expected from retatrutide?

Does retatrutide suppress appetite?

Does retatrutide affect A1C levels?